Nanobiotix, PharmaEngine deal
Nanobiotix granted PharmaEngine exclusive rights to develop and commercialize NBTXR3 in the Asian-Pacific region. Nanobiotix will receive a $1 million upfront payment and is eligible for up to $56 million in milestone payments, plus double-digit royalties. Nanobiotix, which retains rights elsewhere, has the option to re-acquire rights to NBTXR3 in the Asian-Pacific region, except for China and Taiwan, in exchange for termination payments and royalties. PharmaEngine is responsible for funding clinical development in three undisclosed indications, as well as for regulatory activities in the region. The company plans to begin testing in two of the indications in the next 18 months. Nanobiotix said a joint steering committee will approve clinical studies initiated by PharmaEngine. Nanobiotix is planning a Phase I trial in the EU in early 2013. Nanobiotix said the most probable indication for the trial is head and neck cancer. ...